射血分数改善型心力衰竭患者的特征、结局及继续指南导向药物治疗的必要性

数据集获取（Figshare）

• 源站标题：Characteristics, outcomes and the necessity of continued guideline-directed medical therapy in patients with heart failure with improved ejection fraction
• DOI：10.6084/m9.figshare.28043434.v1
• 发布日期：2024-12-17
• 文件数：4 个
• 文件总体积：5.84 MB
• 源站页面：https://tandf.figshare.com/articles/dataset/Characteristics_outcomes_and_the_necessity_of_continued_guideline-directed_medical_therapy_in_patients_with_heart_failure_with_improved_ejection_fraction/28043434

命令行下载

curl -L -o "IANN-2024-0820.R1 Supplementary tables.docx" "https://ndownloader.figshare.com/files/51238454"
curl -L -o "Supplement Figure 1 R1.tif" "https://ndownloader.figshare.com/files/51238457"
curl -L -o "Supplement Figure 2 R1.tif" "https://ndownloader.figshare.com/files/51238460"
curl -L -o "Supplement Figure 3.tif" "https://ndownloader.figshare.com/files/51238463"

文件清单

• IANN-2024-0820.R1 Supplementary tables.docx（38.21 KB）
• Supplement Figure 1 R1.tif（1.88 MB）
• Supplement Figure 2 R1.tif（1.90 MB）
• Supplement Figure 3.tif（2.02 MB）

文件总体积 5.84 MB（源站 API 实测）。

数据加载示例（图像类）

from PIL import Image
import glob, os

files = (glob.glob(os.path.join(path, "**", "*.png"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.jpg"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.tif"), recursive=True))
print("图像文件数:", len(files))
img = Image.open(files[0]); print("尺寸/模式:", img.size, img.mode)

# torchvision Dataset 方式:
# from torchvision import datasets
# ds = datasets.ImageFolder(path)  # 要求 子目录=类别

目录组织与标注格式以源站说明和下载后实际文件为准。

数据说明

Much remains to be learned about patients with heart failure with improved ejection fraction (HFimpEF).
This study sheds light on the characteristics and clinical outcomes of HFimpEF patients, including the consequences of halting guideline-directed medical therapy (GDMT).
This retrospective study was conducted on patients diagnosed with heart failure with reduced ejection fraction (HFrEF) who underwent a second echocardiogram at least 6 months apart between January 2009 and February 2023. The primary outcomes were major adverse cardiovascular events (MACEs), including all-cause mortality and heart failure hospitalization. The second outcome was recurrent HFrEF.
Of 4,560 HFrEF patients were included, 3,289 (72.1%) achieved HFimpEF within a median follow-up period of 3.4 years (IQR: 1.8 − 5.9 years). Among these HFimpEF patients, recurrent HFrEF was observed in 941 (28.6%) patients during a median follow-up period of 2.3 years (IQR: 0.8–4.6 years). The proportion of patients who halted GDMT was 70.4%, 53.2%, 59.8% and 63.8% for MRA, beta-blockers, ACEI/ARB/ARNI and SGLT-2 inhibitors. Multivariable Cox analysis revealed ischemic heart disease, chronic kidney disease, coronary heart disease, lower left ventricular ejection fraction, larger left ventricular diastolic dimension and non-use GDMT are associated with recurrent HFrEF. Individuals without GDMT use exhibited lower chances of persistently recovering ejection fraction and high risks of MACEs compared to those who continue use.
HFimpEF is a common condition across all clinical follow-ups. Prevalent discontinuation of GDMT medications may contribute significantly to recurrent HFrEF, placing patients at a higher risk for poor prognosis.

许可

CC BY 4.0

引用

学术使用请引用 DOI 10.6084/m9.figshare.28043434.v1（source: https://tandf.figshare.com/articles/dataset/Characteristics_outcomes_and_the_necessity_of_continued_guideline-directed_medical_therapy_in_patients_with_heart_failure_with_improved_ejection_fraction/28043434）。